1. The immune landscape of SARS-CoV-2-associated Multisystem Inflammatory Syndrome in Children (MIS-C) from acute disease to recovery
- Author
-
Pamela Kearns, Sascha Ott, Prasad Nagakumar, Wioleta M. Zelek, Scott Hackett, Hari Krishnan Kanthimathinathan, Pavle Vrljicak, Deepthi Jyothish, Eslam Al-Abadi, Pamela Dawson, Naeem Khan, Steven B. Welch, Eanna Fennell, Ashish Chikermane, Alex G. Richter, Sian E Faustini, Eleni Syrimi, Richard Stark, Barnaby R. Scholefield, Kate Davies, Sean Monaghan, Graham S. Taylor, and Paul Murray
- Subjects
Multidisciplinary ,business.industry ,Monocyte ,Science ,Immunology ,Disease ,Genomics ,medicine.disease ,Article ,Complement system ,Arginase ,medicine.anatomical_structure ,Immune system ,Immune system disorder ,Medicine ,Kawasaki disease ,Immune response ,business ,CD163 ,CD8 - Abstract
Multisystem inflammatory syndrome in children (MIS-C) is a life-threatening disease occurring several weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Deep immune profiling showed acute MIS-C patients had highly activated neutrophils, classical monocytes and memory CD8+ T-cells, with increased frequencies of B-cell plasmablasts and double-negative B-cells. Post treatment samples from the same patients, taken during symptom resolution, identified recovery-associated immune features including increased monocyte CD163 levels, emergence of a new population of immature neutrophils and, in some patients, transiently increased plasma arginase. Plasma profiling identified multiple features shared by MIS-C, Kawasaki Disease and COVID-19 and that therapeutic inhibition of IL-6 may be preferable to IL-1 or TNF-α. We identified several potential mechanisms of action for IVIG, the most commonly used drug to treat MIS-C. Finally, we showed systemic complement activation with high plasma C5b-9 levels is common in MIS-C suggesting complement inhibitors could be used to treat the disease., Graphical abstract, Genomics; Immune response; Immune system disorder; Immunology
- Published
- 2021